Cargando…

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting

BACKGROUND: On encountering a susceptible target, natural killer (NK) cells mediate cytotoxicity through highly regulated steps of directed degranulation. Cytotoxic granules converge at the microtubule organizing center and are polarized toward the immunological synapse (IS), followed by granule exo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eitler, Jiri, Wotschel, Natalie, Miller, Nicole, Boissel, Laurent, Klingemann, Hans G, Wels, Winfried, Tonn, Torsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817806/ https://www.ncbi.nlm.nih.gov/pubmed/33468562 http://dx.doi.org/10.1136/jitc-2020-001334

Ejemplares similares

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer
por: Murali Shankar, Nivedha, et al.
Publicado: (2023)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

NK cells engineered to express a GD(2)-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
por: Esser, Ruth, et al.
Publicado: (2012)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor
por: Lou, Chao, et al.
Publicado: (2022)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
por: Zhao, Songbo, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
por: Neo, Shi Yong, et al.
Publicado: (2022)

IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells
por: Landolina, Nadine, et al.
Publicado: (2022)

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
por: Cornel, Annelisa M, et al.
Publicado: (2022)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
por: Bernard, Pierre-Louis, et al.
Publicado: (2022)

PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling
por: Raja, Remya, et al.
Publicado: (2022)

2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis
por: Pan, Banglun, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset
por: Veneziani, Irene, et al.
Publicado: (2022)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis
por: Sun, Mayu, et al.
Publicado: (2021)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation
por: Sun, Yu, et al.
Publicado: (2023)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
por: Fitzgerald, Allison A, et al.
Publicado: (2021)

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy
por: Peng, Peng, et al.
Publicado: (2022)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
por: Graziano, Vincenzo, et al.
Publicado: (2023)

Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma
por: Wu, Hongyan, et al.
Publicado: (2021)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
por: Duurland, Chantal L, et al.
Publicado: (2022)

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019)

Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
por: Silvestre, Renata Nacasaki, et al.
Publicado: (2023)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

“Universal Flu Vaccine”: Can NK Cell-mediated ADCC Tip the Scales?
por: Hassane, Maya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2hqevcttrhj2ds4iiaioufg6ja